Cytoxan

Phase 3Small molecule

UUS Oncology Research

Cytoxan is one of 119 small molecule programs targeting High-Risk Neuroblastoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

118

Competitors

Pipeline

Status by Indication[3][1]

Indication

High-Risk NeuroblastomaRecruiting

Pediatric Solid TumorsActive, not recruiting

RelapseActive, not recruiting

Breast CancerCompleted

NeuroblastomaActive, not recruiting

Stem Cell TransplantationRecruiting

High-Risk NeuroblastomaPhase 2

Recruiting

Pediatric Solid TumorsPhase 1

Active, not recruiting

RelapsePhase 1

Active, not recruiting

Breast CancerPhase 3

Completed

NeuroblastomaPhase 2

Active, not recruiting

Stem Cell TransplantationPhase 2

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Cytoxan

UUS Oncology Research

Phase 3

4 2

Voltaren

Novartis

Preclinical

1 3

Zolymbus

AbbVie

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Duragesic-100

CCephalon

Preclinical

2 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 8

Spravato

WWim Janssens

Preclinical

2 9

Tricor

JJagotec

Preclinical

1 10

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Breast Cancer

NCT06409390

N/ARecruiting

Induction Therapy

NCT05936086

Q3 2027

Phase 1/2Recruiting

Stem Cell Transplantation

NCT04224558

Q3 2029

Phase 2Recruiting

High-Risk Neuroblastoma

NCT06528496

Q4 2030

Phase 1Active, not recruiting

Neuroblastoma

NCT01822652

Clinical

Trials by Indication[1]

Breast Cancer4 trials

Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

Completed·—·Phase 2·NCT00136539·41 enrolled

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06409390·15 enrolled

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00038402·74 enrolled

Show 1 more trial

Adj TC + Herceptin Early Stage Breast Cancer

Completed·UUS Oncology Research·Phase 2·NCT00493649·493 enrolled

Hematologic Malignancies3 trials

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT01203722·87 enrolled

Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT04264078·30 enrolled

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT04264039·30 enrolled

Neuroblastoma2 trials

Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma

Active, not recruiting·—·Phase 1/2·NCT01192555·11 enrolled

3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase Suicide Safety Switch, Neuroblastoma, GRAIN

Active, not recruiting·—·Phase 1·NCT01822652·11 enrolled

Hematological Malignancies2 trials

Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies

Withdrawn·—·N/A·NCT01247688

VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies

Completed·AAlla Keyzner·Phase 1·NCT03885947·7 enrolled

Acute Myeloid Leukemia2 trials

Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT05008575·27 enrolled

Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT05016063·32 enrolled

19 more indications

Multiple Myeloma2 trials

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

Completed·UUniversity of Arkansas·Phase 3·NCT00083551·668 enrolled

Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

Unknown status·XXinqiao Hospital of Chongqing·Phase 1·NCT05008536·27 enrolled

Liver Cancer2 trials

T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)

Withdrawn·—·Phase 1·NCT04093648

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as an Immunotherapy for Children With Solid Tumors (CARE)

Recruiting·BBaylor College of Medicine·Phase 1·NCT04715191·24 enrolled

Transplantation1 trial

DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse

Completed·UUniversity of Arkansas·Phase 2·NCT00083681·180 enrolled

Adenocarcinoma1 trial

A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma

Completed·RRampart Health, L.L.C.·Phase 2·NCT04090775·12 enrolled

Relapse1 trial

HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA

Active, not recruiting·—·Phase 1·NCT02379520·32 enrolled

Chronic Lymphocytic Leukemia1 trial

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

Completed·SSteven E. Coutre·Phase 2·NCT00230282·25 enrolled

Ewing's Sarcoma1 trial

Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

Terminated·SStanford University·Phase 2·NCT01313884·3 enrolled

Safety and Efficacy1 trial

Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00496873·100 enrolled

Pediatric Disorder1 trial

Umbilical Cord Blood Transplant for Congenital Pediatric Disorders

Completed·—·N/A·NCT00950846·40 enrolled

Recurrence1 trial

Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers

Completed·EEmory University·Phase 2·NCT00941330·31 enrolled

Hepatocellular Carcinoma1 trial

Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)

Completed·—·Phase 1·NCT02905188·9 enrolled

Pediatric Solid Tumors1 trial

Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)

Active, not recruiting·—·Phase 1·NCT02932956·10 enrolled

Induction Therapy1 trial

A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH

Recruiting·Sshifeng Lou·N/A·NCT05936086·160 enrolled

Bone Marrow Transplantation1 trial

Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02995330·3 enrolled

Severe Aplastic Anemia1 trial

Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia

Terminated·—·Phase 2·NCT00578903·22 enrolled

Stem Cell Transplantation1 trial

Stem Cell Transplantation in Crohn's Disease

Recruiting·—·Phase 1/2·NCT04224558·15 enrolled

Lymphoma1 trial

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Suspended·—·Phase 2·NCT06692452·24 enrolled

Solid Cancer1 trial

A Phase 2 Trial for Patients With Metastatic Solid Cancer

Active, not recruiting·RRampart Health, L.L.C.·Phase 2·NCT04713371·32 enrolled

High-Risk Neuroblastoma1 trial

N10: Reduced Therapy for High-Risk Neuroblastoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06528496·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for Cytoxan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cytoxan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cytoxan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — US Oncology Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUS Oncology Research

Cytoxan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q3 2029

Q4 2030

Trials by Indication[1]

Breast Cancer4 trials

Hematologic Malignancies3 trials

Neuroblastoma2 trials

Hematological Malignancies2 trials

Acute Myeloid Leukemia2 trials

Multiple Myeloma2 trials

Liver Cancer2 trials

Transplantation1 trial

Adenocarcinoma1 trial

Relapse1 trial

Chronic Lymphocytic Leukemia1 trial

Ewing's Sarcoma1 trial

Safety and Efficacy1 trial

Pediatric Disorder1 trial

Recurrence1 trial

Hepatocellular Carcinoma1 trial

Pediatric Solid Tumors1 trial

Induction Therapy1 trial

Bone Marrow Transplantation1 trial

Severe Aplastic Anemia1 trial

Stem Cell Transplantation1 trial

Lymphoma1 trial

Solid Cancer1 trial

High-Risk Neuroblastoma1 trial

References

Drug Info

Quick Facts

Related News